News & Updates

The final results of the pivotal phase III APPLY-PNH trial show sustained efficacy and safety of the oral factor B inhibitor iptacopan in anti-C5-treated patients with paroxysmal nocturnal haemoglobinuria (PNH) and persistent anaemia.

In the first-line treatment of locally advanced or metastatic nonsmall cell lung cancer (NSCLC) patients with EGFR exon 20 insertion (ex20ins) mutations, the investigational mobocertinib is safe and efficacious but not necessarily better than platinum-based chemotherapy, according to the phase III EXCLAIM-2 trial.

In the treatment of people with mild cognitive impairment, cilostazol is well tolerated but falls short of preventing further cognitive decline, according to the results of the phase II COMCID* trial.

Patients with amphetamine-induced psychosis (AIP) who have been treated with antipsychotics appear to have a longer length of stay (LOS) than those who did not receive such treatment, reports a study.

In a study presented at ESMO Asia 2023, tofacitinib, a rapidly acting JAK-STAT inhibitor with reported efficacy in the treatment of various autoimmune diseases, was effective for the management of difficult-to-treat immune-related adverse events (irAEs) and was well-tolerated in cancer patients, with only a few patients developing infectious events.